Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug:120:147-52.
doi: 10.1016/j.antiviral.2015.06.003. Epub 2015 Jun 10.

The Global Virus Network: Challenging chikungunya

Edward McSweegan  1 , Scott C Weaver  2 , Marc Lecuit  3 , Matthew Frieman  4 , Thomas E Morrison  5 , Sharon Hrynkow  6
Affiliations
Review

The Global Virus Network: Challenging chikungunya

Edward McSweegan et al. Antiviral Res. 2015 Aug.

Abstract

The recent spread of chikungunya virus to the Western Hemisphere, together with the ongoing Ebola epidemic in West Africa, have highlighted the importance of international collaboration in the detection and management of disease outbreaks. In response to this need, the Global Virus Network (GVN) was formed in 2011. The GVN is a coalition of leading medical virologists in 34 affiliated laboratories in 24 countries, who collaborate to share their resources and expertise. The GVN supports research, promotes training for young scientists, serves as a technical resource for governments, businesses and international organizations, facilitates international scientific cooperation, and advocates for funding and evidence-based public policies. In response to the spread of chikungunya, the GVN formed a task force to identify research gaps and opportunities, including models of infection and disease, candidate vaccines and antivirals, epidemiology and vector control measures. Its members also serve as authoritative sources of information for the public, press, and policy-makers. This article forms part of a symposium in Antiviral Research on "Chikungunya discovers the New World".

Keywords: Arbovirus; Chikungunya; Emerging virus; Global Virus Network; Vector-borne.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The global reach of the Global Virus Network. For information about Centers of Excellence, Center Affiliates and participating scientists, go to http://gvn.org/.
See this image and copyright information in PMC

References

    1. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010;16:334–338. - PMC - PubMed
    1. Albulescu IC, Tas A, Scholte FE, Snijder EJ, van Hemert MJ. An in vitro assay to study chikungunya virus RNA synthesis and the mode of action of inhibitors. J Gen Virol. 2014;95:2683–2692. - PubMed
    1. Bourjot M, Leyssen P, Neyts J, Dumontet V, Litaudon M. Trigocherrierin A, a potent inhibitor of chikungunya virus replication. Molecules. 2014;19:3617–3627. - PMC - PubMed
    1. Brandler S, Ruffie C, Combredet C, Brault JB, Najburg V, Prevost MC, Habel A, Tauber E, Despres P, Tangy F. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine. 2013;31:3718–3725. - PubMed
    1. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, Yamshchikov G, Sarwar UN, Hu Z, Enama ME, Bailer RT, Koup RA, Schwartz, Akahata W, Nabel GJ, Mascola JR, Pierson TC, Graham BS, Ledgerwood JE The V.R.C.S.T. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2011;384(9959):2046–2052. - PubMed

MeSH terms